1. Home
  2. CANF

CANF

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Logo Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-24-2024 3:21pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

Founded: 1994 Country:
N/A
Employees: N/A City: N/A
Market Cap: 9.9M IPO Year: N/A
Target Price: $18.00 AVG Volume (30 days): 20.8K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.79 EPS Growth: N/A
52 Week Low/High: $1.64 - $3.33 Next Earning Date: 01-01-0001
Revenue: $743,000 Revenue Growth: -12.90%
Revenue Growth (this year): 1893.41% Revenue Growth (next year): -31.67%

Share on Social Networks: